LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Theravance Biopharma Inc

Theravance Biopharma Inc

Chiusa

16.29 2.45

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15.89

Massimo

16.45

Metriche Chiave
By Trading Economics
Entrata	-66M -4.9M
Vendite	-28M 18M
P/E Media del settore	7.148 49.888
EPS	0.01
Margine di Profitto	-27.872
Dipendenti	90
EBITDA	-26M -6.9M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+7.6% upside

Dividendi
By Dow Jones
Utili prossimi	11 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-49M 822M
Apertura precedente	13.84
Chiusura precedente	16.29

Theravance Biopharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 giu 2026, 21:51 UTC

I principali Market Mover

Merlin Shares Rally After Defense Department's Design Review Wraps

4 giu 2026, 23:46 UTC

Discorsi di Mercato

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 giu 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 giu 2026, 23:42 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 giu 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 giu 2026, 23:34 UTC

Discorsi di Mercato

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

4 giu 2026, 23:08 UTC

Discorsi di Mercato

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 giu 2026, 22:41 UTC

Discorsi di Mercato

Australia Shares Set to Rise at the Open -- Market Talk

4 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 giu 2026, 20:16 UTC

Discorsi di Mercato

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 giu 2026, 19:46 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 giu 2026, 19:38 UTC

Discorsi di Mercato

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 giu 2026, 19:30 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 giu 2026, 18:47 UTC

Acquisizioni, Fusioni, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 giu 2026, 18:38 UTC

Utili

Money Quote: Tech Weakness in Context -- WSJ

4 giu 2026, 18:24 UTC

Utili

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 17:09 UTC

Discorsi di Mercato

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 giu 2026, 16:58 UTC

Utili

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 16:46 UTC

Discorsi di Mercato

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 giu 2026, 16:38 UTC

Utili

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

4 giu 2026, 16:13 UTC

Discorsi di Mercato

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 giu 2026, 16:11 UTC

Discorsi di Mercato

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 giu 2026, 15:56 UTC

Discorsi di Mercato

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Confronto tra pari

Modifica del prezzo

Theravance Biopharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.6% in crescita

Previsioni per 12 mesi

Media 17.13 USD 7.6%

Alto 21 USD

Basso 13.67 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Theravance Biopharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Theravance Biopharma Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.